文献速递神经重症脑血管病外科

神经外科患者丙戊酸钠相关高氨血症的发病率、表现及危险因素:前瞻性观察研究

Incidence, Presentation, and Risk Factors for Sodium Valproate-Associated Hyperammonemia in Neurosurgical Patients: A Prospective, Observational Study.
PubMed 文献 · World Neurosurg · 2020-09-08

该前瞻性队列研究纳入252例使用丙戊酸钠至少一周的成人神经外科患者,发现高氨血症发生率为28%,而丙戊酸钠诱导的高氨血症性脑病仅0.7%。动脉瘤性蛛网膜下腔出血及联用苯妥英或苯巴比妥是高氨血症的独立危险因素。

要点

  • 神经外科患者丙戊酸钠相关高氨血症发生率为28%,但高氨血症性脑病罕见(0.7%)。
  • 动脉瘤性蛛网膜下腔出血及联用苯妥英或苯巴比妥增加高氨血症风险。
  • 丙戊酸钠剂量、疗程、血药浓度及肝功能与高氨血症无关。

核心结论

  • 神经外科患者中丙戊酸钠相关高氨血症常见,但高氨血症性脑病罕见。
  • 动脉瘤性蛛网膜下腔出血或联用酶诱导性抗癫痫药物者风险较高,临床应警惕脑病症状。

研究设计与样本

  • 前瞻性观察性队列研究,纳入252例使用丙戊酸钠至少一周的成人神经外科患者,为期22个月。

主要发现

  • 高氨血症发生率为28%(71/252),高氨血症性脑病发生率为0.7%。
  • 独立危险因素包括动脉瘤性蛛网膜下腔出血(aOR 2.1;95%CI 1.1-4.2)、联用苯妥英(aOR 1.9;95%CI 1.0-3.5)和苯巴比妥(aOR 4.6;95%CI 1.1-20.0)。
  • 丙戊酸钠剂量、疗程、血清水平及肝功能与高氨血症无关联。

临床怎么用

  • 对使用丙戊酸钠的神经外科患者,尤其动脉瘤性蛛网膜下腔出血或联用酶诱导性抗癫痫药物者,应监测高氨血症性脑病症状。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Sodium valproate (VPA) is a commonly prescribed antiepileptic drug (AED) in daily neurosurgical practice. However, the incidence of VPA-associated hyperammonemia (VAH) and its life-threatening consequence, VPA-induced hyperammonemic encephalopathy (VHE), in neurosurgical patients is unknown. We determined the incidence, clinical presentation, and risk factors for VAH. METHODS: This prospective cohort study was performed on adult neurosurgical patients prescribed VPA for at least a week over a 22-month period. Blood tests for ammonia, VPA, and liver function were performed at the time of recruitment. The primary end point was VAH. Secondary end points were VHE and liver dysfunction. RESULTS: In total, 252 patients were recruited. The commonest disease etiology was brain tumors (27%, 69), followed by aneurysmal subarachnoid hemorrhage (SAH; 26%, 65). VPA was prescribed for primary seizure prophylaxis in 110 patients (44%). The mean daily dose was 1148 mg for a mean duration of 48 months. The mean serum VPA level was 417 μmol/L. In total, 92 patients (37%) were prescribed an additional AED, the most common being phenytoin (65%, 60/92). The mean serum ammonia level was 47 μmol/L. In total, 28% (71/252) of patients had VAH and only 0.7% had VHE. Independent factors were aneurysmal SAH (adjusted odds ratio [aOR] 2.1; 95% confidence interval [CI] 1.1-4.2), concomitant phenytoin (aOR 1.9; 95% CI 1.0-3.5), and phenobarbital (aOR 4.6; 95% CI 1.1-20.0). No associations with VPA dose, duration, serum levels, and liver function were observed. CONCLUSIONS: Although VAH is common among neurosurgical patients, VHE is rare. Patients with aneurysmal SAH or on concomitant enzyme-inducing AEDs are at risk. Clinicians should be vigilant for VHE symptoms in these patients.

来源:World Neurosurg,查看原文。版权归原作者所有。

引用

  1. Woo PYM, Woo AWY, Lam SW, et al. Incidence, Presentation, and Risk Factors for Sodium Valproate-Associated Hyperammonemia in Neurosurgical Patients: A Prospective, Observational Study. World Neurosurg. 2020. PMID: 32916358. doi:10.1016/j.wneu.2020.09.027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。